Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer

Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC and Nakamura Y: Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene. 21:4120–4128. 2002. View Article : Google Scholar : PubMed/NCBI

Yagyu R, Furukawa Y, Lin YM, Shimokawa T, Yamamura T and Nakamura Y: A novel oncoprotein RNF43 functions in autocrine manner in colorectal cancer. Int J Oncol. 25:1343–1348. 2004.PubMed/NCBI

Chewawiwat N, Yano M, Terada M, Hoogenraad NJ and Mori M: Characterization of the novel mitochondrial protein import component, Tom34, in mammalian cells. J Biochem. 125:721–727. 1999. View Article : Google Scholar : PubMed/NCBI

Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int J Oncol. 29:381–386. 2006.PubMed/NCBI

Hattori T, Mine T, Komatsu N, et al: Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother. 58:1845–1854. 2009. View Article : Google Scholar

Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y and Tahara H: Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 10:8577–8586. 2004. View Article : Google Scholar : PubMed/NCBI

Shirao K, Hoff PM, Ohtsu A, et al: Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol. 22:3466–3474. 2004. View Article : Google Scholar

Kono K, Mizukami Y, Daigo Y, et al: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509. 2009. View Article : Google Scholar

Correale P, Del Vecchio MT, Genova GD, et al: 5-Fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst. 97:1437–1445. 2005. View Article : Google Scholar

Correale P, Cusi MG, Tsang KY, et al: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 23:8950–8958. 2005.

Nagorsen D and Thiel E: HLA typing demands for peptide-based anti-cancer vaccine. Cancer Immunol Immunother. 57:1903–1910. 2008. View Article : Google Scholar : PubMed/NCBI

Liu K, Wang C, Chen L, et al: Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A0201 and HLA-A2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 10:2645–2651. 2004. View Article : Google Scholar

Weihrauch MR, Ansen S, Jurkiewicz E, et al: Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res. 11:5993–6001. 2005. View Article : Google Scholar

Dittmann J, Keller-Matschke K, Weinschenk T, et al: CD8⁺ T-cell response against MUC-1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol Immunother. 54:750–758. 2005.